Glenmark Celebrates European Ryaltris Approvals
Has Marketing Authorizations In 13 European Countries; Menarini Set To Launch
Executive Summary
Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.
You may also be interested in...
Glenmark’s Ryaltris Set To Hit Canadian Market
Health Canada approves Ryaltris for allergic rhinitis, opening up yet another major market for Glenmark’s branded specialty medicine. Bausch Health will sell the drug in Canada.
Glenmark Chief: Running A Facility In The US Has Been A Struggle
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.
Glenmark Chief: Running A Facility In The US Has Been A Struggle
Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.